Targeting the Nuclear Cathepsin L CCAAT Displacement Protein/Cut Homeobox Transcription Factor-Epithelial Mesenchymal Transition Pathway in Prostate and Breast Cancer Cells with the Z-FY-CHO Inhibitor
- 1 March 2017
- journal article
- Published by Taylor & Francis Ltd in Molecular and Cellular Biology
- Vol. 37 (5)
- https://doi.org/10.1128/mcb.00297-16
Abstract
The Epithelial Mesenchymal Transition (EMT) promotes tumor migration and invasion by downregulating epithelial markers such as E-cadherin and upregulating mesenchymal markers such as vimentin. Cathepsin L (Cat L) is a cysteine protease that can proteolytically activate CCAAT-displacement protein/cut homeobox transcription factor (CUX1). We hypothesized that nuclear Cat L may promote EMT via CUX1, and that this could be antagonized with Cat L specific inhibitor, Z-FY-CHO. Mesenchymal prostate (ARCaP-M, ARCaP-E overexpressing Snail) and breast (MDA-MB-468, MDA-MB-231, and MCF-7 overexpressing Snail) cancer cells expressed lower E-cadherin, higher Snail, vimentin, Cat L activity, and p110/p90 active CUX1 form, as compared to epithelial prostate (ARCaP-E, ARCaP-Neo) and breast (MCF-7, MCF-7 Neo) cancer cells. There was increased binding of CUX1 to Snail and E-cadherin promoter in mesenchymal cells, as compared to epithelial prostate and breast cells. Treatment of mesenchymal cells with Cat L inhibitor, Z-FY-CHO, led to nuclear to cytoplasmic relocalization of Cat L, decreased binding of CUX1 to Snail and E-cadherin promoter, reversed EMT, and decreased cell migration/invasion. Overall, our novel data suggests that a positive feedback loop between Snail-nuclear Cat L-CUX1 drives EMT which can be antagonized by Z-FY-CHO. Therefore, Z-FY-CHO may be an important therapeutic tool to antagonize EMT and cancer progression.Keywords
Funding Information
- HHS | NIH | National Cancer Institute (1F31CA200362-01)
- HHS | NIH | National Institute on Minority Health and Health Disparities (G12RR003062-22)
- HHS | NIH | National Institute on Minority Health and Health Disparities (P20MD002285-01)
This publication has 21 references indexed in Scilit:
- Nuclear cathepsin L activity is required for cell cycle progression of colorectal carcinoma cellsBiochimie, 2016
- Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitorsActa Pharmaceutica Sinica. B, 2015
- Snail Promotes Epithelial Mesenchymal Transition in Breast Cancer Cells in Part via Activation of Nuclear ERK2PLOS ONE, 2014
- The basics of epithelial-mesenchymal transitionJCI Insight, 2009
- Localization of nuclear cathepsin L and its association with disease progression and poor outcome in colorectal cancerInternational Journal of Cancer, 2009
- Cysteine cathepsin proteases as pharmacological targets in cancerTrends in Pharmacological Sciences, 2008
- Increased Expression and Activity of Nuclear Cathepsin L in Cancer Cells Suggests a Novel Mechanism of Cell TransformationMolecular Cancer Research, 2007
- A novel proteolytically processed CDP/Cux isoform of 90 kDa is generated by cathepsin LBiological Chemistry, 2006
- Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial–mesenchymal transitionNature, 2004
- CDP/Cux Stimulates Transcription from the DNA Polymerase α Gene PromoterMolecular and Cellular Biology, 2003